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ABSTRACT Background: Lafora disease (LD; progressive myoclonus epilepsy type 2; EPM2) is an
autosomal recessive disorder caused by mutations in the EPM2A and EPM2B genes. LD is charac-
terized by the presence of strongly PAS-positive intracellular inclusions (Lafora bodies) in several
tissues. Glycogen storage disease type IV (GSD-IV; Andersen disease) is an autosomal recessive
disorder characterized by cirrhosis leading to severe liver failure. GSD-IV has been associated
with mutations in the glycogen branching enzyme gene (GBE). Histopathologic changes of the liver
in both diseases show an identical appearance, although cirrhosis has never been described in
patients with LD. We report a LD family in which the proband presented severe liver failure at
onset of the disease. Methods: Clinical histories, physical and neurologic examination, laboratory
tests, EEGs, MRI of the brain, and liver or axillary skin biopsies were performed in the two affected
siblings. The diagnosis was confirmed by molecular genetic analysis of the EPM2A, EPM2B, and GBE
genes and loci. Results: During the first decade of life, abnormalities in liver function tests were de-
tected in the two affected siblings. The proband’s liver dysfunction was severe enough to require liver
transplantation. Subsequently, both sibs developed LD. Mutation analysis of EPM2A revealed a ho-
mozygous Arg241stop mutation in both patients. Conclusions: This is the first description of severe
hepatic dysfunction as the initial clinical manifestation of LD. The phenotypic differences between the
two affected siblings suggest that modifier genes must condition clinical expression of the disease
outside the CNS. NEUROLOGY 2007;68:1369–1373
Accumulation of polyglucosans represents the morphologic manifestation of several clini-
cally heterogeneous disorders such as Lafora disease, glycogen storage disease type IV, adult
polyglucosan body disease, and some cases of phosphofructokinase deficiency (Tauri
disease).
Lafora disease or progressive myoclonus epilepsy of the Lafora type (EPM2 [MIN254780])
is an autosomal recessive form of progressive myoclonus epilepsy (PME) that initially mani-
fests during adolescence and is characterized by epilepsy, myoclonus, and progressive neuro-
logic deterioration. The diagnosis is sustained by the presence of periodic acid-Schiff (PAS)
positive glycogen-like intracellular inclusion bodies (Lafora bodies). Lafora bodies, first de-
scribed by Gonzalo R. Lafora in 1911, consist of an abnormal glucose polymer.1,2 Lafora
originally called the inclusion bodies “intracellular amyloid bodies” when he observed them
in the brain and spinal cord of an adolescent patient who presented a progressive and fatal
form of myoclonic epilepsy. In 1955, Harriman and Millar showed that the inclusions were
not limited to the CNS and described similar intracellular inclusions in the heart and liver of
one patient with Lafora disease.3 Lafora disease initially manifests during adolescence, the
most common age at onset being between 10 and 17 years. Generalized tonic-clonic seizures,
absences, drop attacks, or partial visual seizures are usually the first manifestation, followed
soon after by asymmetric as well as massive myoclonic jerks. As the disease progresses, the
myoclonus increases in frequency and becomes constant. A rapidly progressive dementia
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with apraxia, aphasia, and visual loss ensues,
leading patients to a vegetative stage and
death, usually within less than a decade of
first symptoms. Two genes have been associ-
ated with Lafora disease: EPM2A (chromo-
some 6q24) and EPM2B (chromosome
6p22.3). EPM2A encodes a protein tyrosine
phosphatase (LAFPTPase or laforin).4,5 In
spite of the remarkable allelic heterogeneity
in the EPM2A gene, the R241stop mutation
has been found in approximately 40% of
Lafora disease patients with mutations in
this gene.6,7 The EPM2B gene (also called
NHLRC1) encodes an E3 ubiquitin ligase
(malin) and the most frequent mutation
found is P69A.8
Glycogen storage disease or glycogenosis
type IV, also known as amylopectinosis or
Andersen disease (MIN23250), is an autoso-
mal recessive disorder caused by a deficiency
of glycogen-branching enzyme (GBE) activ-
ity due to mutations in the GBE1 gene.9 A
diagnosis can be made on the basis of the
study of branching enzyme activity in eryth-
rocytes.10 Glycogenosis type IV is highly het-
erogeneous in terms of tissue involvement,
clinical manifestations, and age at onset. The
classic form of glycogenosis type IV is char-
acterized by rapidly progressive hepato-
splenomegaly and liver failure leading to
either liver transplantation or death by the
age of 5 years.9 In addition to the classic
form, variants such as a milder nonprogres-
sive hepatic disease,11 neuromuscular forms
varying in onset and severity (from a fatal
neonatal disease12 to a mild adult myop-
athy13), a cardiopathic form of childhood,14
or a variant with multisystem involvement
including liver and muscle15 have been re-
ported. GBE belongs to the alpha-amylase
family and is required for glycogen synthesis.
It catalyzes the formation of alpha 1,6-
glucosidic branches that play an important
role increasing the solubility of the molecule
and is most highly expressed in liver and
muscle. Typically, hepatocytes in glycogeno-
sis type IV contain glycogen PAS-positive in-
clusions resulting in a ground glass
appearance. This stored glycogen shows
fewer branch points and longer outer chains
resembling amylopectin. For this reason the
disease is also referred to as amylopectinosis.
Ultrastructurally, the inclusion bodies of
Lafora disease and glycogenosis type IV ap-
pear quite similar.16 Liver fibrosis, which can
progress to cirrhosis, is a frequent finding in
glycogenosis type IV. However, only mild to
moderate periportal fibrosis has been de-
scribed in the liver of patients with Lafora
disease.17
Here, we present a clinical and molecular
genetic study of two siblings with Lafora dis-
ease, one of whom developed a progressive
liver cirrhosis and failure, requiring liver
transplantation.
METHODS Patients and samples. We studied two sib-
lings from a Spanish family (figure 1A). Both presented epi-
lepsy, myoclonus, rapidly progressive neurologic deterioration,
and a slow background activity with polyspike-wave com-
plexes in the EEG.18,19 A biopsy of skin from the proband and
liver biopsy from the younger brother showed the characteristic
PAS-positive Lafora bodies in both. Blood was collected from
patients and their relatives after informed consent.
DNA samples were obtained from peripheral blood lym-
phocytes using standard methods. The study was approved by
the Ethics Committee of the Fundacio´n Jime´nez Dı´az.
Microsatellite analysis. Analysis of microsatellite polymor-
phisms on chromosomes 6q24 and 3p12 was performed by PCR
using total human genomic DNA. Amplification was per-
formed in a total volume of 10 L containing 40 ng of genomic
DNA and isotopic phosphate. Samples were resolved on 6.5%
polyacrylamide sequencing gels and bands were visualized us-
ing Kodak XAR films for 1 to 14 hours.
Single-strand conformational polymorphism (SSCP)
analysis. SSCP analysis20 was performed by PCR, using total
genomic DNA, using the GenePhor DNA Electrophoresis Sys-
tem (Amersham Pharmacia Biotech). Amplification was per-
formed in a total volume of 10 L containing 60 ng of genomic
DNA. Samples were resolved on 12.5% non-denaturing poly-
acrylamide gels with the GeneGel Excel 12.5/24 kit (Amersham
Figure 1 Spanish Lafora disease family
(A) Spanish Lafora disease
family. Black symbols
indicate affected individuals.
(B) Single-strand
conformational
polymorphism analysis.
Individuals LD122-1,
LD122-2, and LD122-3 are
denoted as 1, 2, and 3.
Individual C1 is an unaffected
control. Individual C2 is
affected with the
Arg241stop mutation in
homozygosis. Individuals 1
and 2 carry the mutation in
heterozygosis and Individual
3 in homozygosis. (C) DNA
sequence of exon 4 of the
EPM2A gene showing the
C¡T change resulting in the
replacement of arginine 241
by a stop codon.
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Pharmacia Biotech) and silver stained using the PlusOne DNA
Silver Staining Kit (Amersham Pharmacia Biotech).
Sequencing of exons. Exons 1, 2, 3, and 4 of the EPM2A
gene,6 exon 1 of the EPM2B gene,8 and exons 1 to 16 of theGBE
gene were amplified from genomic DNA with specific primers
using standard methods. The corresponding PCR products
were purified by agarose gel electrophoresis and extracted with
the Qiaquick Gel Extraction Kit (Qiagen). Direct sequencing of
PCR products was performed with a dye-terminator cycle-
sequencing kit (Perkin-Elmer) using Taq FS DNA polymerase.
Sequences were resolved on an ABI PRISM 377 automatic se-
quencer, and the results analyzed with the ABI Analysis soft-
ware (version 3.1).
RESULTS Clinical findings. Case 1. The proband
presented growth retardation with height and
weight deficiencies since early infancy. At age 7, lab-
oratory tests revealed an increase in hepatic
transaminase levels (alanine aminotransferase 321,
aspartate aminotransferase 380) and abdominal dis-
tension, ascites, and increasing splenomegaly due to
portal hypertension appeared. Hemorrhagic com-
plications occurred subsequently and a severe he-
patic failure was detected. A liver biopsy was
performed at age 9. The histopathologic study
showed ground-glass appearance of hepatocytes
demonstrating positive Best carmine staining and
lack of staining with orcein. Severe periportal stel-
late fibrosis was observed suggesting type IV glyco-
gen storage disease (figure 2, A and B). He required
liver transplantation at age 10. No clinical compli-
cations occurred during follow-up.
At age 16 he noticed transient light spots during a
school test. He had his first generalized tonic-clonic
seizure the following day. Six months later, myo-
clonic jerks were noticed. At first, these were asym-
metric, segmental myoclonic jerks and occurred
occasionally. During the following year, generalized
tonic-clonic seizures increased in frequency and
massive myoclonus appeared. Seizures were refrac-
tory to antiepileptic drugs. Progressive intellectual
impairment occurred during the next 2 years.
An EEG showed diffuse slow background activ-
ity with bilateral paroxysms of spike-wave and
polyspike-wave complexes. Marked photosensitiv-
ity was noted. Brain magnetic resonance showed ce-
rebral atrophy and typical Lafora bodies were seen
in an axillary skin biopsy.
Case 2.The proband’s younger brother presented
an increase of liver transaminases levels in a routine
analysis at age 6 (alanine aminotransferase 112, as-
partate aminotransferase 80). Although he re-
mained clinically asymptomatic, a liver biopsy was
performed at age 9. Liver biopsy revealed PAS-
positive intracellular inclusion bodies with normal
lobular architecture. No periportal fibrosis was ob-
served. At age 14 he initially noticed occasional epi-
sodes consisting of seeing sudden and transient
brilliant spots. These episodes lasted for few sec-
onds and were especially frequent when he was
watching television. Massive myoclonic jerks ap-
peared 3 months later and he had his first general-
ized tonic-clonic seizure 1 year after the onset of
neurologic symptoms. EEG showed a slow back-
ground activity, occipital spikes increasing with in-
termittent photic stimulation, and paroxysms of
irregular spike-wave activity on both frontotempo-
ral regions. During follow-up, myoclonic epilepsy
and neurologic deterioration progressively devel-
oped but no hepatic dysfunction was detected.
Genetic findings. SSCP and mutational analysis of
exons 1, 2, 3, and 4 of the EPM2A gene revealed a
homozygous Arg241stop mutation in both siblings
(figure 1, B and C), confirming the diagnosis of
Lafora disease. Exons 1 to 16 of the GBE gene and
exon 1 of EPM2B gene were also analyzed in both
siblings in order to search for mutations. No muta-
tions were found.
Figure 2 Histologic study of the liver of Individual LD112-3
(A) Histologic study of the
liver of Individual LD112-3
showing loss of hepatic
structure and confluent
bands of collagen forming
nodules (Masson’s trichromic
stain). (B) Ground-glass
appearance of hepatocytes
as expression of the Lafora
bodies (arrow).
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Haplotype analysis of the EPM2A and GBE
genes was also performed and showed that both rel-
atives presented identical haplotype for these loci
(data not shown).
DISCUSSION Lafora disease has been considered a
clinically homogeneous degenerative disorder mani-
fested by progressive myoclonic epilepsy. Atypical
Lafora disease with an early onset cognitive deficit
phenotype has been recently reported by different
authors in a minority of patients.21-23 However, in
no case of Lafora disease caused by mutations in
EPM2A or EPM2B genes have initial clinical symp-
toms outside the CNS been reported. Here we de-
scribe the first Lafora disease family in which the
proband presented a severe liver failure resembling
glycogenosis type IV at onset of the disease. His
younger brother showed abnormal liver function
tests in a routine analysis although he was clinically
asymptomatic and no signs of hepatic failure were
detected during his follow-up. Both siblings subse-
quently developed the typical picture of progressive
myoclonus epilepsy of Lafora type. PAS-positive in-
clusions were observed in an axillary skin biopsy
from the proband and in a liver biopsy from his
younger brother. The diagnosis of Lafora disease
was confirmed by mutation analysis of the EPM2A
gene, which revealed an Arg241stop mutation in ho-
mozygosis in both siblings. Interestingly, only the
proband presented severe liver failure preceding the
onset of progressive myoclonus epilepsy.
Histopathologic study of the liver in the proband
showed ground-glass appearance of hepatocytes
with PAS-positive inclusions and cirrhosis, leading
to the diagnosis of glycogenosis type IV. His-
topathologic changes of the liver in Lafora disease
and glycogenosis type IV show an identical appear-
ance. The similarity applies especially to the ground
glass hepatocytes containing PAS-positive inclu-
sions. Histochemical reactions of stored material
are similar. However, patients with glycogenosis
type IV typically develop cirrhosis while only mild
to moderate periportal fibrosis has been described
in patients with Lafora disease.17 The clinical pic-
ture and the histopathologic findings in the proband
strongly suggested the diagnosis of glycogenosis
type IV. Mutation analysis of the complete coding
region of theGBE gene did not reveal any mutations
and haplotype analysis of the chromosomal region
containing the GBE gene revealed identical haplo-
types for both sibs, suggesting that this gene is not
responsible for the liver failure present in the
proband.
Similarities between Lafora and glycogenosis
type IV diseases suggest that these two conditions
are closely related and may share a common meta-
bolic disturbance conditioning failures at different
levels of the same metabolic pathway. Concomitant
enzyme deficiencies in the same individual causing an
unusual glycogenosis with extensive neuronal polyglu-
cosan storage has been reported.24 This is an extremely
rare condition but it is reasonable to think that a simi-
lar situation may account for the unusual clinical find-
ings found in the patient here presented. This patient
presents a combination of two different clinical pheno-
types included in the group of glycogen metabolic
pathway disorders. A homozygous mutation in
EPM2A and no mutation in GBE were found. The
most plausible hypothesis is that other unidentified
modifier genes or genes involved in glycogen metabo-
lism might condition the clinical expression of Lafora
disease outside the CNS.
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